Latest Administration News

Page 27 of 184
The NSW Department of Planning and Environment has approved a six-year extension for the Dartbrook underground coal mine, pushing its operational horizon to 2033 despite ongoing financial administration challenges.
Maxwell Dee
Maxwell Dee
4 Mar 2026
Island Pharmaceuticals has entered a pivotal research agreement with USAMRIID and the Geneva Foundation to accelerate FDA approval of Galidesivir for Marburg Virus Disease, leveraging top-tier US biodefense expertise.
Victor Sage
Victor Sage
4 Mar 2026
ADX Energy has released an updated assessment of its Welchau well in Austria, revealing a significant increase in prospective gas-condensate and light oil resources. The 2024 drilling results highlight promising reservoir conditions and pave the way for further appraisal.
Maxwell Dee
Maxwell Dee
3 Mar 2026
Avecho Biotechnology has completed recruitment for the interim analysis cohort of its pivotal Phase III trial for a CBD insomnia treatment, with results expected in June 2026. This milestone could significantly de-risk the program and unlock major market opportunities.
Ada Torres
Ada Torres
2 Mar 2026
Eden Innovations Ltd reports a $1.43 million half-year profit, reversing prior losses thanks to a $4.45 million property sale and significant debt reduction, while advancing international commercialisation of its concrete and fuel technologies.
Maxwell Dee
Maxwell Dee
27 Feb 2026
Platformo Ltd reported a modest 5% revenue increase in 2025 driven by its Malaysian subsidiary Biztrak, but faced a higher net loss due to regulatory delays and increased corporate advisory costs.
Sophie Babbage
Sophie Babbage
27 Feb 2026
Peak Processing Limited reported a sharp 47.7% revenue drop and a 257.7% increase in losses for H1 2026, alongside a significant asset impairment and ongoing going concern concerns.
Ada Torres
Ada Torres
27 Feb 2026
Recce Pharmaceuticals reported a doubling of its net loss for the half-year ended December 2025 amid significant progress in its anti-infective drug development and a substantial funding boost. The company is advancing Phase 3 trials and expanding its patent portfolio while managing financial pressures.
Ada Torres
Ada Torres
27 Feb 2026
Epsilon Healthcare Limited has reported a robust recovery in 2025, with revenue climbing 68% to $9.39 million and net losses shrinking by 63%, driven by growth in contract manufacturing and a new pharmacy division.
Ada Torres
Ada Torres
27 Feb 2026
Janus Electric Holdings reported a 46% increase in net loss to $4.93 million for the half-year ended December 2025, driven by rising costs despite a 33% revenue boost. The company faces funding uncertainties as it pursues key investments and operational scale-up.
Maxwell Dee
Maxwell Dee
27 Feb 2026
1414 Degrees Ltd posted a steep 192% rise in half-year losses to $3.86 million, while advancing its silicon-based energy storage and hydrogen technologies. The company also faces uncertainty after its joint venture partner Vast Renewables entered administration.
Maxwell Dee
Maxwell Dee
27 Feb 2026
Avecho Biotechnology reported a 9.3% revenue increase alongside a 41.5% rise in net loss for 2025, while progressing its Phase III CBD insomnia trial and securing a significant licensing agreement with Sandoz.
Ada Torres
Ada Torres
27 Feb 2026